Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibitor of androgen biosynthesis
|
| gptkbp:affects |
improves overall survival
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:brand |
Zytiga
|
| gptkbp:can_be_used_with |
gptkb:prednisone
|
| gptkbp:clinical_trial |
Phase III
hormonal therapy |
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
pregnancy
severe liver impairment |
| gptkbp:discovered_by |
gptkb:University_of_California,_Los_Angeles
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
abiraterone
|
| gptkbp:indication |
metastatic castration-resistant prostate cancer
high-risk metastatic hormone-sensitive prostate cancer |
| gptkbp:ingredients |
C21 H28 N2 O3
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors CY P17 A1 inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
L02 B X03
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
approximately 12 hours
improves quality of life |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Janssen_Biotech
|
| gptkbp:metabolism |
liver
|
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:research |
used in clinical trials
well-tolerated in patients delays disease progression effective in combination with chemotherapy reduces PSA levels |
| gptkbp:research_areas |
oncology
|
| gptkbp:side_effect |
fatigue
nausea hypertension adrenal insufficiency liver toxicity joint pain cardiovascular events hypokalemia weight gain hot flashes |
| gptkbp:targets |
androgen receptor
|
| gptkbp:type_of |
154229-19-3
|
| gptkbp:bfsParent |
gptkb:ALX-0688
gptkb:ALX-0706 gptkb:ALX-0718 |
| gptkbp:bfsLayer |
5
|